Literature DB >> 16428918

Screening for nephropathy and antiangiotensin use among diabetic patients in an academic community medical center.

Lawrence A Frazee1, Seyhoon Samandari, Natthavat Tanphaichitr, Claire C Bourguet, Eugene W Pfister.   

Abstract

The American Diabetes Association recommends routine screening for albuminuria to detect early nephropathy in all patients with diabetes mellitus. If nephropathy is identified, treatment with an antiangiotensin agent decreases progression and improves renal outcomes. Concordance with guidelines for nephropathy screening and antiangiotensin therapy among diabetic patients in a primary care setting of an academic community medical center was evaluated. Medical charts of adult patients with diabetes mellitus from February 2000 through January 2003 were retrospectively reviewed. In part 1 of the study, whether patients were screened for nephropathy at least once was recorded. In part 2 of the study, antiangiotensin prescribing was assessed in all patients and in subgroups stratified by screening. In both parts of the study, patient characteristics and comorbidities were assessed using multivariate analysis to determine their impact on the odds that a patient was screened and that antiangiotensin therapy was prescribed. Among the 329 patients included, 182 patients (55.3%) were screened for nephropathy. Patients who were screened were younger (OR=0.83 for 10-year increase, 95% CI: 0.69-0.99), less likely to have congestive heart failure (OR=0.42, 95% CI: 0.20-0.90), and more likely to be cared for by a resident physician directly supervised by an attending physician (OR=3.03; 95% CI: 1.82-5.03). A total of 215 patients (65.3%) were prescribed antiangiotensin therapy. Hypertension was a predictor of antiangiotensin therapy among all patients who were screened (OR=10.34, 95% CI: 4.45-24.01), those who were screened and negative (OR=15.46, 95% CI: 5.56-42.98), and those who were not screened (OR=10.79, 95% CI: 4.39-26.52). Among patients screened for nephropathy, coronary artery disease (OR=3.01, 95% CI: 1.05-8.63), and the presence of proteinuria (OR=4.26, 95% CI: 1.61-11.24) were predictors of antiangiotensin use. This study found that the likelihood of screening for nephropathy among diabetic patients was inversely associated with a diagnosis of congestive heart failure and increasing age. Conversely, care by a resident physician directly supervised by an attending physician increased the odds that patients would be screened. A diagnosis of hypertension and the presence of albuminuria were each associated with increased use of an antiangiotensin agent.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16428918     DOI: 10.1097/01.mjt.0000174345.59177.9b

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  4 in total

1.  The effect of screening for cardio-renal risk factors on drug use in the general population.

Authors:  Jarir Atthobari; Ron T Gansevoort; Sipke T Visser; Paul E de Jong; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2007-12       Impact factor: 4.335

2.  Development and validation of a self-assessment tool for albuminuria: results from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Paul Muntner; Mark Woodward; April P Carson; Suzanne E Judd; Emily B Levitan; Devin M Mann; William McClellan; David G Warnock
Journal:  Am J Kidney Dis       Date:  2011-05-26       Impact factor: 8.860

Review 3.  Identification and management of albuminuria in the primary care setting.

Authors:  Louis Kuritzky; Robert Toto; Peter Van Buren
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-02-01       Impact factor: 3.738

4.  The Clinical Utility of SUDOSCAN in Chronic Kidney Disease in Chinese Patients with Type 2 Diabetes.

Authors:  Andrea O Y Luk; Wai-Chi Fu; Xue Li; Risa Ozaki; Harriet H Y Chung; Rebecca Y M Wong; Wing-Yee So; Francis C C Chow; Juliana C N Chan
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.